Wirtschaftsverband Chemie Pharma Life Sciences

Panel discussion at the scienceindustries Online-GV

At the scienceindustries General Assembly, the Minister of Economic Affairs, Guy Parmelin, and personalities from the chemical, pharmaceutical and life sciences industries discussed the impact of the redundancy and corporate responsibility initiative for Switzerland.

04.09.2020

Dr. Matthias Leuenberger, President of scienceindustries, informs after the welcome speech about the results and business of the association. Afterwards, he focusses on: The industry impact of the Corona pandemic and the outlook for current initiatives and challenges for our industries

Federal Councillor Guy Parmelin, Head of the Federal Department of Economics, Education and Research (WBF), explains the importance of a business-friendly environment, inter alia in connection with the dismissal initiative

Dr. Klaus Moosmayer, Member of the Executive Committee and Chief Ethics, Risk and Compliance Officer of Novartis, comments on the Corporate Responsibility Initiative

Erik Fyrwald, CEO Syngenta Group, looks at crop protection initiatives and their real impact

Esther Keller, moderator, leads through the discussions.


Close

Newsletter subscription

Quarterly Newsletter
Standpoints

 
 

Foreign trade statistics chemistry pharma life science

Further analyzes

Export Chemicals Pharma Life Sciences Switzerland by region

Further analyzes